GRcalculator: an online tool for calculating and mining dose–response data
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
BACKGROUND: , are confounded by the number of cell divisions taking place during the assay, which varies widely for biological and experimental reasons. Hafner et al. (Nat Meth 13:521-627, 2016) recently proposed an alternative way to quantify drug response, normalized growth rate (GR) inhibition, that is robust to such confounders. Adoption of the GR method is expected to improve the reproducibility of dose-response assays and the reliability of pharmacogenomic associations (Hafner et al. 500-502, 2017). RESULTS: We describe here an interactive website ( www.grcalculator.org ) for calculation, analysis, and visualization of dose-response data using the GR approach and for comparison of GR and traditional metrics. Data can be user-supplied or derived from published datasets. The web tools are implemented in the form of three integrated Shiny applications (grcalculator, grbrowser, and grtutorial) deployed through a Shiny server. Intuitive graphical user interfaces (GUIs) allow for interactive analysis and visualization of data. The Shiny applications make use of two R packages (shinyLi and GRmetrics) specifically developed for this purpose. The GRmetrics R package is also available via Bioconductor and can be used for offline data analysis and visualization. Source code for the Shiny applications and associated packages (shinyLi and GRmetrics) can be accessed at www.github.com/uc-bd2k/grcalculator and www.github.com/datarail/gr_metrics . CONCLUSIONS: GRcalculator is a powerful, user-friendly, and free tool to facilitate analysis of dose-response data. It generates publication-ready figures and provides a unified platform for investigators to analyze dose-response data across diverse cell types and perturbagens (including drugs, biological ligands, RNAi, etc.). GRcalculator also provides access to data collected by the NIH LINCS Program ( http://www.lincsproject.org /) and other public domain datasets. The GRmetrics Bioconductor package provides computationally trained users with a platform for offline analysis of dose-response data and facilitates inclusion of GR metrics calculations within existing R analysis pipelines. These tools are therefore well suited to users in academia as well as industry.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Fig. 6 grbrowser use-case with gCSI data. An example use-case of the grbrowser with the gCSI dataset, reproducing a result from Hafner et al. [3]. Steps show how to use the grbrowser to filter the dataset to breast cancer cell lines treated with lapatinib and compare the sensitivity of wild-type PTEN cell lines with that of mutant PTEN cell lines using GR 50 and IC 50. In this case, use of the GR 50 produces a known result (p-value 0.0033), that PTEN loss-of-function mutations mediate resistance to lapatinib in breast cancer cells, which IC 50 fails to produce at a statistically significant level (p-value 0.12) because of large differences in growth rates between the wild-type and mutant cell lines. p-values were calculated using a two-sided Wilcoxon rank-sum test. IC 50 and GR 50 values were capped at 31 μM](https://figures.cochat.ai/paper-figures/878f5b4ac881462c86459cd93eb24834/grcalculator-an-online-tool-for-calculating-and-mining-doseresponse-data-figure-6.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In addition, there have been multiple reports demonstrating differences in the ability of KRAS G12D to more effectively facilitate PI3K effector interactions and pathway activation compared with KRAS G12C or other KRAS variants providing further rationale for the co-targeting strategy with direct PI3K α inhibitors in KRAS G12D mutant cancers independently of tumor type [39, 40].”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [39]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 15 · Cited by 121
Research works printed but not linked: 2
- Niepel M, Hafner M, Duan Q, Wang Z, Paull EO, Chung M, Lu X, Stuart JM, Golub TR, Subramanian A, Ma'ayan A, Sorger PK. Transcriptional landscape of drug response guides the design of specific and potent drug combinations. Nat Commun. In Press.
- Hafner M, Niepel M, Sorger PK. Alternative drug sensitivity metrics improve preclinical cancer pharmacogenomics. Nat Biotech. 2017;35:500–2. · DOI · Paper page
Metadata
- Authors
- Clark, N. A., Hafner, M., Kouril, M., Williams, E. H., Muhlich, J. L., Pilarczyk, M., Niepel, M., Sorger, P. K., & Medvedovic, M.
- Affiliations
- University of Cincinnati (US)
- Harvard University (US)
- Cincinnati Children's Hospital Medical Center (US)
- Corresponding author
- Medvedovic, Mario
- ORCID
- Venue
- BMC Cancer
- Published
- 2017-10-24
- Volume
- 17
- Issue
- 1
- Pages
- 698-698
- ISSN
- 1471-2407 (ISSN-L)
- PMC
- PMC5655815
- OpenAlex
- W2554439427
- Cited by
- 121
- References
- 15
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 23 · 2023: 28 · 2022: 16 · 2021: 8 · 2020: 12 · 2019: 6 · 2018: 4 · 2017: 3
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- BMC Cancer (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Institutes of Health (U54-HL127624, U54-HL127365)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biophysics › Cell Image Analysis Techniques
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Keywords
- dose-response analysis, Shiny app, pharmacogenomics, data visualization, R/Bioconductor package
- MeSH terms
- Animals, Cell Line, Dose-Response Relationship, Drug, Humans, Software, Reproducibility of Results, Data Mining
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GRcalculator: an online tool for calculating and mining dose–response data. https://app.cochat.ai/papers/10.1186/s12885-017-3689-3
- The paper
- Clark, N. A., Hafner, M., Kouril, M., Williams, E. H., Muhlich, J. L., Pilarczyk, M., Niepel, M., Sorger, P. K., & Medvedovic, M. (2017). GRcalculator: an online tool for calculating and mining dose–response data. BMC Cancer. https://doi.org/10.1186/s12885-017-3689-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.